---
title: "Impaired clathrin recruitment to phosphorylated B cell receptor in diffuse large B cell lymphoma"
id: "biorxiv-20-clathrin-recruitment-and-assembly-of-phosphorylated-b-cell-receptor-is-impaired"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-20-clathrin-recruitment-and-assembly-of-phosphorylated-b-cell-receptor-is-impaired"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.09.22.753512v1?rss=1"
published_at: "2026-09-23T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Impaired clathrin recruitment to phosphorylated B cell receptor in diffuse large B cell lymphoma
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-20-clathrin-recruitment-and-assembly-of-phosphorylated-b-cell-receptor-is-impaired
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.09.22.753512v1?rss=1)
- **Published At:** 2026-09-23T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study examines the spatial organization of the **B cell receptor (BCR)** and its components in a human model of the activated B cell–like (**ABC DLBCL**) subtype of **diffuse large B cell lymphoma**. - The BCR is composed of a membrane-bound **surface immunoglobulin (sIg)** that binds antigen and two coreceptor subunits, **CD79A** and **CD79B**, whose intracellular domains drive signaling and receptor endocytosis in healthy B cells. - Using correlative super-resolution light microscopy and platinum replica transmission electron microscopy, the authors mapped BCR components relative to plasma membrane structures; specific experimental parameters were not reported in the source abstract. - Spontaneous clusters of the common sIg in ABC lymphoma localized to **smooth raised membrane domains** that are implicated in endocytosis of large receptor clusters. - Activated, **phosphorylated CD79A (pCD79A)** showed minimal colocalization with **clathrin**, both on and off smooth raised membranes, indicating impaired clathrin recruitment/assembly to phosphorylated receptors. - pCD79A was spatially segregated from both the sIg and **CD79B** subunits of the BCR complex; a similar segregation pattern was observed for downstream phosphorylated Src family kinases. - The authors propose that disengagement of **pCD79A** from sIg and CD79B prevents normal endocytic down-regulation, allowing persistent plasma-membrane signaling that could drive aberrant survival and proliferation in lymphomas. - The report is a preprint and has not undergone peer review; competing interests were declared as none. Details such as sample numbers, quantitative metrics, and full methodological parameters are not provided in the abstract.
## Clinical Analysis & Structured Key Points
Clathrin recruitment and assembly of phosphorylated B cell receptor is impaired in human diffuse large B cell lymphoma | bioRxiv Skip to main content New Results Clathrin recruitment and assembly of phosphorylated B cell receptor is impaired in human diffuse large B cell lymphoma Aleah D Roberts , Kem Sochacki , Louis Staudt , Justin W Taraska doi: https://doi.org/10.64898/2026.09.22.753512 Aleah D Roberts 1 The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kem Sochacki 2 National Heart Lung and Blood Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Louis Staudt 3 National Cancer Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Justin W Taraska 4 National Institutes of Health Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: justin.taraska{at}nih.gov Abstract Info/History Metrics Supplementary material Preview PDF Abstract The B cell receptor (BCR) drives the differentiation of naive B cells into activated plasma cells that produce antibodies. The BCR consists of a plasma membrane-bound surface immunoglobulin (sIg) that binds antigens, and two coreceptor subunits CD79A and CD79B. The intracellular domains of CD79A and CD79B initiate immune signaling and endocytosis of the receptor in healthy B cells. In diffuse large B cell lymphoma (DLBCL), an aggressive form of human blood cancer, the activated B cell like (ABC) subtype exhibits constitutive signaling that drives survival and proliferation. Here, in a model of human ABC DLBCL, we determine the localization of BCR components relative to plasma membrane structures using correlative super-resolution light and platinum replica transmission electron microscopy. We find that spontaneous clusters of the surface Immunoglobulin common to ABC lymphoma localize to smooth raised membrane domains. These structures are involved in the endocytosis of large receptor clusters. Surprisingly, activated phosphorylated CD79A (pCD79A) shows little colocalization with clathrin on or off smooth raised membranes. Furthermore, pCD79A spatially segregates away from both the slg and CD79B subunits of the BCR complex. A similar distribution was found for downstream phosphorylated Src family kinases. We propose that a disengagement of pCD79A away from sIg and CD79B allows the receptor to evade down-regulation through endocytosis and maintains signaling at the plasma membrane. This mechanism could drive aberrant signaling and the proliferation of lymphomas leading to disease. Competing Interest Statement The authors have declared no competing interest. Funder Information Declared National Institute of General Medical Sciences, https://ror.org/04q48ey07 , K99GM152952 , R00GM152952 Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. Back to top Previous Next Posted September 23, 2026. Download PDF Supplementary Material Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Clathrin recruitment and assembly of phosphorylated B cell receptor is impaired in human diffuse large B cell lymphoma Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Clathrin recruitment and assembly of phosphorylated B cell receptor is impaired in human diffuse large B cell lymphoma Aleah D Roberts , Kem Sochacki , Louis Staudt , Justin W Taraska bioRxiv 2026.09.22.753512; doi: https://doi.org/10.64898/2026.09.22.753512 Share This Article: Copy Citation Tools Clathrin recruitment and assembly of phosphorylated B cell receptor is impaired in human diffuse large B cell lymphoma Aleah D Roberts , Kem Sochacki , Louis Staudt , Justin W Taraska bioRxiv 2026.09.22.753512; doi: https://doi.org/10.64898/2026.09.22.753512 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Animal Behavior and Cognition (8021) Biochemistry (18781) Bioengineering (14921) Bioinformatics (44492) Biophysics (22625) Cancer Biology (19761) Cell Biology (26945) Clinical Trials (138) Developmental Biology (13993) Ecology (21037) Epidemiology (2067) Evolutionary Biology (25473) Genetics (16185) Genomics (23535) Immunology (18725) Microbiology (42548) Molecular Biology (18095) Neuroscience (93601) Paleontology (701) Pathology (2987) Pharmacology and Toxicology (5104) Physiology (8127) Plant Biology (16020) Scientific Communication and Education (2097) Synthetic Biology (4572) Systems Biology (10251) Zoology (2393)
## Related Clinical Research

- [Chinese Medical Association 2026 Guideline: Clinical Diagnosis and Treatment of Lung Cancer](https://medichelpline.com/clinical-feed/pubmed-42764215.md) (DOI: 10.3760/cma.j.cn112152-20260511-00228)
- [Cysteine (N‑acetylcysteine) reverses immune dysfunction in cancer patients with severe COVID‑19](https://medichelpline.com/clinical-feed/medrxiv-7-cysteine-supplementation-reverses-immune-dysfunction-in-cancer-patients-with.md)
- [RENOIR Phase 3: Rituximab–Lenalidomide versus Rituximab Maintenance in Relapsed/Refractory Follicu](https://medichelpline.com/clinical-feed/pubmed-42349017.md) (DOI: 10.1182/bloodadvances.2025018732)
- [Palmitoylation-related Signature Predicts Prognosis and Immune Microenvironment in DLBCL](https://medichelpline.com/clinical-feed/frontiers-in-immunology-8-a-palmitoylation-related-signature-predicts-prognosis-and-immune.md)
- [Blood test trends versus single abnormal results to detect cancer in patients with unexpected weig](https://medichelpline.com/clinical-feed/plos-medicine-1-blood-test-trend-versus-single-threshold-abnormality-to-discriminate-cancer.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.